| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/27/2005 | EP1524973A1 A pharmaceutical composition useful for treating chronic myeloid leukemia |
| 04/27/2005 | EP1524972A2 Compounds with antiparasitic activity and medicines containing same |
| 04/27/2005 | EP1524971A1 Improved transdermal delivery system |
| 04/27/2005 | EP1524969A2 Microcapsules with modified release of active principles with low solubility for oral delivery |
| 04/27/2005 | EP1524967A1 Pharmaceutical preparation containing a benzimidazole compound mixed with microcrystalline cellulose and a method for its preparation |
| 04/27/2005 | EP1524966A1 Taste masked oral composition of telithromycin |
| 04/27/2005 | EP1524965A2 Stabilization of the profile of release of active substances from a formulation |
| 04/27/2005 | EP1524912A1 Compositions comprising lactoferrin |
| 04/27/2005 | EP1463723A4 Process for the preparation of simvastatin |
| 04/27/2005 | EP1461316A4 Synthesis of 2-cyanoziridine-1-carboxamide |
| 04/27/2005 | EP1456193B1 PREPARATION OF TRANS-FUSED 3,3a,8,12b-TETRAHYDRO-2 i H /i -DIBENZO 3,4:6,7]CYCLOHEPTA 1,2-b]FURAN DERIVATIVES |
| 04/27/2005 | EP1455799B1 Pharmaceutical combinations of adenosine a-2a and beta-2-adrenergic receptor agonists |
| 04/27/2005 | EP1448207B1 Dosage regimen and pharmaceutical composition for emergency contraception |
| 04/27/2005 | EP1429628B1 Mixture of base-containing micronutrient substances |
| 04/27/2005 | EP1424996B1 Method for the production of inhalation powders |
| 04/27/2005 | EP1423367B1 Solvates of lercanidipine hydrochloride and crystalline forms of lercanidipine hydrochloride |
| 04/27/2005 | EP1423110A4 Cbi analogues of cc-1065 and the duocarmycins |
| 04/27/2005 | EP1419150B1 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use |
| 04/27/2005 | EP1381311A4 Methods and reagents to acquire mri signals and images |
| 04/27/2005 | EP1374873B1 The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for supressing side-effect of radiotherapy and chemotherapy |
| 04/27/2005 | EP1370513B1 Malic acid addition salts of terbinafine |
| 04/27/2005 | EP1363614B1 Use of 2-amino-1-(4-hydroxy-3-methanesulphonamidophenyl)ethanol for treating urinary incontinence |
| 04/27/2005 | EP1357910B1 Method for preventing and treating visceral pain and gastrointestinal disorders |
| 04/27/2005 | EP1330246B1 Use of hydroxyeicosatetraenoic acid derivatives in intraocular surgery |
| 04/27/2005 | EP1325010B1 Substituted 3.4-dihydro-pyrimido [1,2-a]pyrimidines and 3.4-dihydropyrazino [1,2-a]pyrimidines |
| 04/27/2005 | EP1289519A4 Methods of treating androgen deficiency in men using selective antiestrogens |
| 04/27/2005 | EP1286668B1 Pharmaceutical combinations comprising tegaserod und omeprazole and their use in treating gastrointestinal disorders |
| 04/27/2005 | EP1261327B1 Adenosine receptor modulators |
| 04/27/2005 | EP1244662B1 Pyridazino quinoline derivative and method for the treatment of pain |
| 04/27/2005 | EP1242307B1 Method for preparing ortho silicic acid, ortho silicic acid as obtained, and its use |
| 04/27/2005 | EP1225814B1 Fibrous-liponutritional complexes and compositions containing them |
| 04/27/2005 | EP1220620B1 Composition comprising casein protein and whey protein |
| 04/27/2005 | EP1217993B1 Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
| 04/27/2005 | EP1175220B1 Nanoparticulate eplerenone compositions |
| 04/27/2005 | EP1150707B1 USE OF AN OmpA ENTEROBACTERIUM PROTEIN ASSOCIATED WITH THE ELAGIGILTV PEPTIDE FOR TREATING MELANOMAS |
| 04/27/2005 | EP1144411B1 Antihistaminic spiro compounds |
| 04/27/2005 | EP1143974B1 Pharmaceutical compositions for alleviating discomfort |
| 04/27/2005 | EP1139974A4 Soy depigmenting and skin care compositions |
| 04/27/2005 | EP1131323B1 Synthesis of acyclic nucleoside derivatives |
| 04/27/2005 | EP1128834B1 Combinations for diabetes which contain glyburide,troglitazone (and a biguanide) |
| 04/27/2005 | EP1105122B1 Pharmaceutical compositions containing lipase inhibitors |
| 04/27/2005 | EP1073470B1 Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients |
| 04/27/2005 | EP1061929B1 Pharmaceutical composition based on natural synthesis progesterone and oestradiol and preparation method |
| 04/27/2005 | EP1056458B1 Treatment of chronic pain |
| 04/27/2005 | EP1040098B1 Integrin receptor antagonists |
| 04/27/2005 | EP1037596B1 Long-acting, chemical-resistant skin emollients, moisturizers, and strengtheners |
| 04/27/2005 | EP1034173B1 Method for producing 8-methoxy-quinoline carboxylic acids |
| 04/27/2005 | EP1033997B1 Method of mobilizing hematopoietic stem cells |
| 04/27/2005 | EP1015019B1 Compositions and methods of therapy for igf-i-responsive conditions |
| 04/27/2005 | EP1011651B1 Method of treating diabetes and related disease states |
| 04/27/2005 | EP0994853B1 A monoether of probucol and methods for the inhibition of the expression of vcam-1 |
| 04/27/2005 | EP0979072B1 Transdermal device for the delivery of testosterone |
| 04/27/2005 | EP0964861B1 Process for the production of tetrazolylbenzopyrans |
| 04/27/2005 | EP0942733B1 Use of nk-1 receptor antagonists for treating cognitive disorders |
| 04/27/2005 | EP0931077B1 Substituted benzocycloheptapyridine useful as inhibitors of farnesyl-protein transferase |
| 04/27/2005 | EP0918515B1 USE OF INHIBITORS OF THE CELLULAR Na+ /H+ EXCHANGER (NHE) FOR PREPARING A MEDICAMENT FOR NORMALIZING SERUM LIPIDS |
| 04/27/2005 | EP0910572B1 Inhibitors of picornavirus 3c proteases and methods for their use and preparation |
| 04/27/2005 | EP0906307B1 Substituted imidazoles having cytokine inhibitory activity |
| 04/27/2005 | EP0873519A4 Hiv protease inhibitors |
| 04/27/2005 | EP0850068B1 Lipid extract having anti-inflammatory activity |
| 04/27/2005 | EP0838453B1 Heterocyclic carboxylic acid derivatives and drugs containing the same |
| 04/27/2005 | EP0833651B1 Analgesic use of n-l-alpha-aspartyl-l-phenylalanine 1-methyl ester |
| 04/27/2005 | EP0741569B1 Naphthylisoquinoline alkaloids, pharmaceutical compositions containing them and their use for the treatment of malaria |
| 04/27/2005 | CN1610743A Gene differentially expressed in breast and bladder cancer and encoded polypeptides |
| 04/27/2005 | CN1610695A Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| 04/27/2005 | CN1610691A 2-O-(beta-D-glucopyranosyl)ascorbic acid, process for its production, and foods and cosmetics containing compositions comprising it |
| 04/27/2005 | CN1610690A Method for preparing a glucosamine compound, and compound thus obtained |
| 04/27/2005 | CN1610684A Novel multi-ring organic compounds for regulating gut motility and food intake |
| 04/27/2005 | CN1610683A Pyrimidotriazines as phosphatase inhibitors |
| 04/27/2005 | CN1610681A Polycyclic compounds having anti-tumor activity |
| 04/27/2005 | CN1610680A Process for preparing scopine esters |
| 04/27/2005 | CN1610679A Efficient process for the preparation of a factor XA inhibitor |
| 04/27/2005 | CN1610676A Compounds and method for the treatment of overactive bladder |
| 04/27/2005 | CN1610675A Benzothiazole- and benzoxazole-4, 7-dione derivatives and their use as CDC25 phosphatase inhibitors |
| 04/27/2005 | CN1610674A Use of 2-amino-thiazoline derivatives as inhibitors of inducible NO-synthase |
| 04/27/2005 | CN1610671A Quinoline compounds with 5-HT-antagonistic properties for therapy |
| 04/27/2005 | CN1610670A 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists |
| 04/27/2005 | CN1610669A Heteroaryl-substituted aminocyclohexane derivatives |
| 04/27/2005 | CN1610668A Substituted propane-1, 3-diamine derivatives and the pharmaceutical use |
| 04/27/2005 | CN1610667A 3-nitropyridine derivaives and the pharmaceutical compositions containing said derivatives |
| 04/27/2005 | CN1610666A Benzamidine derivative |
| 04/27/2005 | CN1610665A Process for preparation of cyanophenylbenzoic acid derivatives |
| 04/27/2005 | CN1610664A 3-azabicyclo (3.1.0) hexane derivatives as opioid receptor antagonists |
| 04/27/2005 | CN1610662A Method of obtaining novel lutein-based formulations |
| 04/27/2005 | CN1610661A Allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
| 04/27/2005 | CN1610659A Carboxylic acid derivative |
| 04/27/2005 | CN1610567A Enhanced systemic absorption of intradermally delivered substances |
| 04/27/2005 | CN1610564A Compositions and methods of using collajolie |
| 04/27/2005 | CN1610559A Prostaglandin composition for the treatment of erectile dysfunction |
| 04/27/2005 | CN1610558A Aspirin-containing transdermal pharmaceutical composition for the treatment of calcification |
| 04/27/2005 | CN1610557A 6-fluorobicyclo 3.1.0 hexane derivatives |
| 04/27/2005 | CN1610554A Chinese herbal medicine composition with treating heatstroke purpose and preparing method thereof |
| 04/27/2005 | CN1610553A Nucleic acid-based compounds and methods of use thereof |
| 04/27/2005 | CN1610552A Antipruritics |
| 04/27/2005 | CN1610551A Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic |
| 04/27/2005 | CN1610550A Pharmaceutical formulations comprising an immune response modifier |
| 04/27/2005 | CN1610549A Epermycin derivative for treating difficult to cure tumor |
| 04/27/2005 | CN1610548A Use of irbesartan for the preparation of medicaments that are used to prevent or treat pulmonary hypertension |
| 04/27/2005 | CN1610547A N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor |
| 04/27/2005 | CN1610546A 病毒聚合酶抑制剂 Viral polymerase inhibitor |